Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/ijms22073781
Keywords
Parkinson’ s disease; dopamine receptor; non motor symptoms
Funding
- Fondazione CARIPLO [2011-0504]
- Fondazione UBI per Varese Onlus [18/7/2017]
- AGING PROJECT-Department of Excellence-Universita del Piemonte Orientale
- Fondazione Cariplo
Ask authors/readers for more resources
Parkinson's disease is a neurodegenerative disorder caused by loss of dopaminergic neurons. Treatment relies on dopaminergic replacement, but genetic factors can influence the clinical progression and drug response in patients. Understanding the genetic variability of dopaminergic receptors may provide insights into the development of personalized therapies for PD.
Parkinson's disease (PD) is a neurodegenerative disease caused by loss of dopaminergic neurons in the midbrain. PD is clinically characterized by a variety of motor and nonmotor symptoms, and treatment relies on dopaminergic replacement. Beyond a common pathological hallmark, PD patients may present differences in both clinical progression and response to drug therapy that are partly affected by genetic factors. Despite extensive knowledge on genetic variability of dopaminergic receptors (DR), few studies have addressed their relevance as possible influencers of clinical heterogeneity in PD patients. In this review, we summarized available evidence regarding the role of genetic polymorphisms in DR as possible determinants of PD development, progression and treatment response. Moreover, we examined the role of DR in the modulation of peripheral immunity, in light of the emerging role of the peripheral immune system in PD pathophysiology. A better understanding of all these aspects represents an important step towards the development of precise and personalized disease-modifying therapies for PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available